AKUMS DRUGS AND PHARMA L
Latest filings
- Subsidiary gets Rs 52.75 cr NPPA demand notice over drug pricing · Regulatory & Legal
- Routine RTA compliance certificate for Q2 FY27 dematerialisation · Compliance
- Trading window closed from Oct 1 ahead of Q2 results · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹4,502 Cr over the trailing twelve months.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Nothing flagged in the filed numbers.Charts
How has the market priced it — with filings on the timeline?
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from AKUMS DRUGS AND PHARMA L's filed financials and exchange disclosures
What does AKUMS DRUGS AND PHARMA L do?
AKUMS DRUGS AND PHARMA L is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol AKUMS.
Is AKUMS DRUGS AND PHARMA L profitable?
Yes. Over the trailing twelve months AKUMS DRUGS AND PHARMA L reported a net profit of ₹293 Cr on revenue of ₹4,502 Cr.
Does AKUMS DRUGS AND PHARMA L pay a dividend?
Not in the latest reported year — AKUMS DRUGS AND PHARMA L's dividend payout for FY26 was nil.
Is AKUMS DRUGS AND PHARMA L debt-free?
On a net basis, yes. It reported borrowings of ₹73 Cr on its 31 Mar 2026 balance sheet, but holds ₹313 Cr more cash than debt.
Is AKUMS DRUGS AND PHARMA L expensive compared with its peers?
On trailing P/E, AKUMS DRUGS AND PHARMA L ranks 98 of 158 in Pharmaceuticals — cheaper than 38% of them, against an industry median of 30.1×. This is a position, not a valuation judgement.
How much does the AKUMS DRUGS AND PHARMA L share price move in a day?
On a typical session AKUMS DRUGS AND PHARMA L moves 1.28% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.
Where can I track AKUMS DRUGS AND PHARMA L's announcements?
Every NSE and BSE filing by AKUMS DRUGS AND PHARMA L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.